Genedrive PLC Result of AGM (9013U)
28 November 2019 - 3:23AM
UK Regulatory
TIDMGDR
RNS Number : 9013U
Genedrive PLC
27 November 2019
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces that at the Annual General Meeting, held today,
all resolutions proposed were duly passed.
For information, details of the proxy voting are shown
below:
Resolution Votes For Votes For Votes Votes Against Votes Withheld
(as % of Against (as % of
votes cast) votes cast)
1. Receive the Annual
report and accounts
for the Company 22,673,789 100.0% 0 0.00% 515
----------- ------------- --------- -------------- ---------------
2. Approve the Directors'
Remuneration Report 21,886,545 96.5% 787,131 3.47% 628
----------- ------------- --------- -------------- ---------------
3. Re-appoint Tom
Lindsay as a director 22,674,304 100.0% 0 0.00% 0
----------- ------------- --------- -------------- ---------------
4. Re-appoint Chris
Yates as a director 22,674,304 100.0% 0 0.00% 0
----------- ------------- --------- -------------- ---------------
5. Re-appoint David
Budd as a director 22,674,304 100.0% 0 0.00% 0
----------- ------------- --------- -------------- ---------------
6. Re-appoint Matthew
Fowler as a director 22,674,304 100.0% 0 0.00% 0
----------- ------------- --------- -------------- ---------------
7. Re-appoint Ian
Gilham as a director 21,887,370 100.0% 314 0.00% 786,620
----------- ------------- --------- -------------- ---------------
8. Appoint RSM UK
as auditors of the
Company 22,674,304 100.0% 0 0.00% 0
----------- ------------- --------- -------------- ---------------
9. Directors' authority
to allot shares 22,109,087 100.0% 0 0.00% 565,217
----------- ------------- --------- -------------- ---------------
10. Disapplication
of pre-emption rights 19,551,681 88.4% 2,556,891 11.57% 565,732
----------- ------------- --------- -------------- ---------------
The full text of each of the resolutions is set out in the
notice of Annual General Meeting, copies of which are available on
the Company's website (www.genedriveplc.com).
- Ends -
For further details please contact:
genedrive plc www.genedriveplc.com
David Budd: CEO / Matthew Fowler:
CFO +44 (0)161 989 0245
Peel Hunt LLP +44 (0)20 7418 8900
James Steel / Oliver Jackson
Stanford Capital Partners Limited +44 (0)20 3815 8880
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Investor Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) mt-RNR1-ID kit has received CE-IVD
Certification and will be launched into Europe and other markets
following full evaluation by the UK National Health Service. The
Company has assays on market for the detection of HCV, certain
military biological targets, and has tests in development for
tuberculosis (mTB).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGBLBDBGDDBGCR
(END) Dow Jones Newswires
November 27, 2019 11:23 ET (16:23 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
